Boehringer Ingelheim Venture Fund co-led the cancer immunotherapy developer's series A round, which also featured Illumina Ventures.

Repeatome drug developer Rome Therapeutics is based on intellectual property from Massachusetts General Hospital and Icahn School of Medicine at Mount Sinai.

JHU-founded restorative materials technology developer Lifesprout secured $28.5m in a round led by Redmile Group as it looks to move into regenerative medicine.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Medytox-backed restorative materials technology developer Lifesprout secured $28.5m in a round led by Redmile Group as it looks to move into regenerative medicine.

Otsuka Pharmaceuticals's McQuade Center for Strategic Research and Development backed the psilocybin-based mental health drug developer through the round.

Repeatome drug developer Rome Therapeutics was incubated within GV, which took part in the series A round along with fellow corporate unit Partners Innovation Fund.

Cancer therapy developer Oric, whose backers include Memorial Sloan, Taiho and Hartford HealthCare, floated at the top of its range in an expanded IPO.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.